Tarsus Pharmaceuticals (NASDAQ:TARS) Director William Phd Link Sells 12,500 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Director William Phd Link sold 12,500 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total value of $979,750.00. Following the completion of the sale, the director owned 94,487 shares in the company, valued at approximately $7,405,891.06. This trade represents a 11.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Trading Up 1.8%

TARS stock opened at $79.03 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.20 and a quick ratio of 3.17. The company has a fifty day moving average price of $69.02 and a two-hundred day moving average price of $66.73. Tarsus Pharmaceuticals, Inc. has a one year low of $51.57 and a one year high of $91.53. The stock has a market cap of $3.47 billion, a price-to-earnings ratio of -72.50 and a beta of 0.54.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). The company had revenue of $173.91 million during the quarter, compared to the consensus estimate of $169.65 million. Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. Equities analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -2.4 EPS for the current year.

Wall Street Analyst Weigh In

TARS has been the subject of several research reports. Mizuho cut their price objective on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Barclays started coverage on Tarsus Pharmaceuticals in a research report on Wednesday. They issued an “overweight” rating and a $110.00 target price on the stock. Jefferies Financial Group increased their target price on Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a research note on Tuesday, September 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Finally, Oppenheimer boosted their price target on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $94.00.

Institutional Trading of Tarsus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of TARS. BlackRock Inc. bought a new position in shares of Tarsus Pharmaceuticals in the second quarter worth $242,705,000. Jupiter Topco LLC acquired a new position in Tarsus Pharmaceuticals in the second quarter valued at about $176,834,000. Janus Henderson Group PLC lifted its position in Tarsus Pharmaceuticals by 16.1% during the first quarter. Janus Henderson Group PLC now owns 2,240,963 shares of the company’s stock worth $157,223,000 after purchasing an additional 310,638 shares during the period. Assenagon Asset Management S.A. lifted its position in Tarsus Pharmaceuticals by 13.5% during the first quarter. Assenagon Asset Management S.A. now owns 1,280,194 shares of the company’s stock worth $89,806,000 after purchasing an additional 152,464 shares during the period. Finally, Bank of America Corp DE grew its stake in Tarsus Pharmaceuticals by 57.5% during the first quarter. Bank of America Corp DE now owns 1,194,377 shares of the company’s stock worth $83,786,000 after buying an additional 436,271 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye conditions with significant unmet medical needs. The company’s lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, a prescription eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, a common eyelid disorder associated with an infestation of Demodex mites.

XDEMVY is designed to target and eliminate Demodex mites, addressing an underlying cause of the disease rather than only managing its symptoms.